Please use this identifier to cite or link to this item:
|Title:||Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children|
Live attenuated influenza vaccine
|Source:||Lum, L.C.S., Borja-Tabora, C.F., Breiman, R.F., Brooks, W.A., Vesikari, T., Sablan, B.P., Chay, O.M., Tantracheewathorn, T., Schmitt, H.-J., Lau, Y.-L., Bowonkiratikachorn, P., Tam, J.S., Lee, B.W., Tan, K.K., Pejcz, J., Cha, S., Gutierrez-Brito, M., Kaltenis, P., Vertruyen, A., Czajka, H., Bojarskas, J., Cheng, S.-M., Rappaport, R., Baker, S., Gruber, W.C., Forrest, B.D. (2010). Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 28 (6) : 1566-1574. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2009.11.054|
|Abstract:||Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35 ± 7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV + Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively). © 2009 Elsevier Ltd. All rights reserved.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 7, 2018
WEB OF SCIENCETM
checked on Feb 5, 2018
checked on Mar 11, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.